BR112015009975A2 - métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal - Google Patents
métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinalInfo
- Publication number
- BR112015009975A2 BR112015009975A2 BR112015009975A BR112015009975A BR112015009975A2 BR 112015009975 A2 BR112015009975 A2 BR 112015009975A2 BR 112015009975 A BR112015009975 A BR 112015009975A BR 112015009975 A BR112015009975 A BR 112015009975A BR 112015009975 A2 BR112015009975 A2 BR 112015009975A2
- Authority
- BR
- Brazil
- Prior art keywords
- gastrointestinal tract
- riboflavin
- salt
- stimulation
- composition
- Prior art date
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 241000894006 Bacteria Species 0.000 title abstract 4
- 230000009286 beneficial effect Effects 0.000 title abstract 4
- 230000000638 stimulation Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 4
- 235000015872 dietary supplement Nutrition 0.000 abstract 4
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 abstract 4
- 229960002477 riboflavin Drugs 0.000 abstract 4
- 235000019192 riboflavin Nutrition 0.000 abstract 4
- 239000002151 riboflavin Substances 0.000 abstract 4
- 229950001574 riboflavin phosphate Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- 241000605980 Faecalibacterium prausnitzii Species 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 235000013305 food Nutrition 0.000 abstract 2
- 238000012423 maintenance Methods 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000019722 synbiotics Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
abstract the invention relates to supporting the growth or maintenance of oxygen-sensitive bacteria in the gastrointestinal tract of an animal. provided is the use of riboflavin, riboflavin phosphate or a salt thereof, for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of faecalibacterium prausnitzii in the gastrointestinal tract. also provided is a synbiotic composition comprising living beneficial butyrate-producing anaerobic bacteria formulated with riboflavin, riboflavin phosphate or a salt thereof, and cysteine. ____________________ tradução do resumo resumo patente de invenção: "métodos e composiçãos para a estimulação das bactérias benéficas no trato gastrointestinal". a invenção refere-se à sustentação do crescimento ou ma-nutenção de bactérias sensíveis ao oxigênio no trato gastrointestinal de um animal. é fornecido o uso de riboflavina, fosfato de riboflavina ou um sal deste, para a preparação de uma composição alimentícia, composição farmacêutica, suplemento alimentício ou dietético, para o estímulo seletivo de faecalibacterium prausnitzii no trato gastrointesti-nal. também é fornecida uma composição simbiótica que compreende bactérias anaeróbicas benéficas vivas produtoras de butirato formula-da com riboflavina, fosfato de riboflavina ou um sal deste, e cisteína.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190948 | 2012-11-01 | ||
| US201261728811P | 2012-11-21 | 2012-11-21 | |
| PCT/NL2013/050781 WO2014070014A1 (en) | 2012-11-01 | 2013-11-01 | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015009975A2 true BR112015009975A2 (pt) | 2017-07-11 |
Family
ID=47148630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015009975A BR112015009975A2 (pt) | 2012-11-01 | 2013-11-01 | métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150283144A1 (pt) |
| EP (2) | EP3345606A1 (pt) |
| JP (2) | JP2015535280A (pt) |
| AU (1) | AU2013338774B2 (pt) |
| BR (1) | BR112015009975A2 (pt) |
| WO (1) | WO2014070014A1 (pt) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN110201003A (zh) | 2012-02-29 | 2019-09-06 | 伊西康内外科公司 | 微生物区系的组合物及与其相关的方法 |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| FI127483B (en) * | 2014-06-11 | 2018-07-13 | Gut Guide Oy | Microbial marker for celiac disease and related product |
| GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| JP6427278B2 (ja) | 2014-12-23 | 2018-11-21 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | ｐｉｒｉｎポリペプチド及び免疫モジュレーション |
| SI3065748T1 (en) | 2014-12-23 | 2018-05-31 | 4D Pharma Research Limited | Severe bacteroid tethethioomycron and its use in reducing inflammation |
| TWI829098B (zh) | 2015-01-02 | 2024-01-11 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| TWI788111B (zh) | 2015-01-02 | 2022-12-21 | 美商梅拉洛伊卡公司 | 多元補充品組成物 |
| US10137164B2 (en) | 2015-01-02 | 2018-11-27 | Melaleuca, Inc. | Dietary supplement compositions |
| EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
| ES2909456T3 (es) | 2015-05-22 | 2022-05-06 | Univ Arizona State | Métodos para tratar el trastorno del espectro autista y síntomas asociados |
| EP3307906B1 (en) * | 2015-06-09 | 2020-10-14 | Regents of the University of Minnesota | Methods for detecting risk of having a bloodstream infection |
| RS59446B1 (sr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti |
| CN114984057A (zh) | 2015-06-15 | 2022-09-02 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SI3360559T1 (sl) | 2015-06-15 | 2020-02-28 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
| GB201519087D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | Method for adaption |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP3209310B1 (en) | 2015-11-20 | 2018-01-31 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
| NZ745678A (en) | 2016-03-04 | 2019-03-29 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2017210428A1 (en) * | 2016-06-01 | 2017-12-07 | Crestovo Llc | Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders |
| EP3850953B1 (en) * | 2016-06-10 | 2023-11-01 | N.V. Nutricia | Nutrition to reduce the risk of allergy |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| AU2018272291A1 (en) | 2017-05-22 | 2020-01-16 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| JP2020521760A (ja) | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
| JP6898674B2 (ja) | 2017-06-02 | 2021-07-07 | グッドガット エッセ．エッレ． | ディスバイオシスの治療のために用いられるブドウ果皮 |
| ES2917415T3 (es) | 2017-06-14 | 2022-07-08 | 4D Pharma Res Ltd | Composiciones que comprenden una cepa bacteriana |
| CN111107859B (zh) | 2017-06-14 | 2022-04-29 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| HUE052319T2 (hu) | 2017-06-14 | 2021-04-28 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| CN111328284A (zh) | 2017-08-07 | 2020-06-23 | 芬奇治疗公司 | 用于维持和恢复健康的肠道屏障的组合物和方法 |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| WO2019086427A1 (en) | 2017-11-03 | 2019-05-09 | Dsm Ip Assets B.V. | New delivery system |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| US20220288103A1 (en) * | 2018-08-29 | 2022-09-15 | Dsm Ip Assets B.V. | Formulations for improving gut health |
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
| EP3920934A1 (en) * | 2019-02-04 | 2021-12-15 | DSM IP Assets B.V. | Therapeutic combinations and compositions for the treatment of inflammatory bowel disease (ii) |
| CN113382733A (zh) * | 2019-02-04 | 2021-09-10 | 帝斯曼知识产权资产管理有限公司 | 用于治疗炎性肠病的治疗性组合和组合物 |
| KR20220139955A (ko) | 2020-02-12 | 2022-10-17 | 디에스엠 아이피 어셋츠 비.브이. | 장으로의 산화방지제의 직접 전달 |
| WO2022090254A1 (en) | 2020-10-28 | 2022-05-05 | Dsm Ip Assets B.V. | Direct delivery of vitamins to inhibit microbial pathogens |
| US20230404970A1 (en) | 2020-10-28 | 2023-12-21 | Dsm Ip Assets B.V. | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics |
| WO2023176951A1 (ja) | 2022-03-18 | 2023-09-21 | 株式会社明治 | Ｃｏｌｌｉｎｓｅｌｌａ属細菌の増殖制御用組成物及びその利用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59132884A (ja) * | 1983-01-20 | 1984-07-31 | Dai Ichi Seiyaku Co Ltd | ビフイズス菌増殖促進組成物 |
| ATE442143T1 (de) * | 2001-03-21 | 2009-09-15 | Eisai R&D Man Co Ltd | Reduziertes vitamin b2 enthaltende arzneimittel |
| JP2004059488A (ja) * | 2002-07-29 | 2004-02-26 | Asahi Food & Healthcare Ltd | 乳酸菌整腸組成物および食品 |
| DK1562447T3 (da) * | 2002-10-23 | 2009-04-06 | Quercegen Holdings Llc | Antioxidative sammensætninger |
| ES2235642B2 (es) * | 2003-12-18 | 2006-03-01 | Gat Formulation Gmbh | Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos. |
| JP6006117B2 (ja) * | 2009-11-12 | 2016-10-12 | ネステク ソシエテ アノニム | 腸内微生物叢バランス及び健康を促進するための栄養組成物 |
| EP2451467B1 (en) | 2010-01-14 | 2016-12-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs) |
| NL2004201C2 (en) * | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
| ES2389547B1 (es) * | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. |
-
2013
- 2013-11-01 US US14/439,882 patent/US20150283144A1/en not_active Abandoned
- 2013-11-01 BR BR112015009975A patent/BR112015009975A2/pt not_active Application Discontinuation
- 2013-11-01 EP EP18157821.2A patent/EP3345606A1/en not_active Withdrawn
- 2013-11-01 EP EP13795881.5A patent/EP2914135A1/en not_active Withdrawn
- 2013-11-01 JP JP2015540630A patent/JP2015535280A/ja active Pending
- 2013-11-01 AU AU2013338774A patent/AU2013338774B2/en not_active Ceased
- 2013-11-01 WO PCT/NL2013/050781 patent/WO2014070014A1/en active Application Filing
-
2018
- 2018-03-09 US US15/916,704 patent/US20180207165A1/en not_active Abandoned
- 2018-03-12 JP JP2018043874A patent/JP2018111711A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180207165A1 (en) | 2018-07-26 |
| AU2013338774A1 (en) | 2015-05-21 |
| AU2013338774B2 (en) | 2017-03-02 |
| EP2914135A1 (en) | 2015-09-09 |
| EP3345606A1 (en) | 2018-07-11 |
| JP2018111711A (ja) | 2018-07-19 |
| US20150283144A1 (en) | 2015-10-08 |
| JP2015535280A (ja) | 2015-12-10 |
| WO2014070014A1 (en) | 2014-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015009975A2 (pt) | métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal | |
| BR112013019258A8 (pt) | Uso de uma formulação probiótica compreendendo uma cepa de bifidobacterium bifidum | |
| BR112014031658A2 (pt) | método mixotrófico de aquicultura | |
| UA112080C2 (uk) | Спосіб одержання водоростевої біомаси і її використання | |
| WO2015026235A3 (en) | Production of probiotics by in vitro enrichment of beneficial microorganisms from human or animal microbiota | |
| BRPI1009860A8 (pt) | composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais | |
| CL2011000891A1 (es) | Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales. | |
| BR112013026661A2 (pt) | método de entrega de vacina | |
| BR112014019927A8 (pt) | fórmula nutricional, método de preparação da referida fórmula antes da sua ingestão por um indivíduo, uso da referida fórmula, dispositivo para prepará-la e recipiente | |
| BR112012033666A2 (pt) | formulações para alimentação por tubo e métodos de uso das mesmas | |
| BR112015022833A2 (pt) | bactéria de ácido láctico ou um fragmento da mesma, bactéria de ácido láctico isolada ou um fragmento da mesma, uso de bactérias de ácido láctico ou um fragmento das mesmas, composição alimentícia, método para conservação de gêneros alimentícios, e, método de identificação de uma bactéria de ácido láctico | |
| MX350870B (es) | Formula para lactantes con alto palmitato sn-2 y oligofructosa. | |
| CL2007002084A1 (es) | Ingrediente lacteo enriquecido en fosfolipidos y esfingolipidos, en que el porcentaje de fosfolipidos es mayor a 36% con respeto al peso de la materia seca del ingrediente; procedimiento de obtencion; composicion alimentaria o aditivo que lo contiene; composicion farmaceutica o cosmetica; y su uso. | |
| MX2013010076A (es) | Composiciones y metodos que comprenden c16:1n7 palmitoleato. | |
| BR112014009097A2 (pt) | composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos | |
| BR112012028592A2 (pt) | método para fabricação de uma composição de glicosaminoglicano, composição de glicosaminoglicano, seus usos e preparação adequada para aplicação à pele ou membrana mucosa | |
| FI3389407T3 (fi) | Ravintokoostumus ja äidinmaidonkorvike de novo myelinaation edistämiseksi | |
| BR112014010448A2 (pt) | microorganismos e métodos para a produção de caprolactona | |
| BR112013028709A2 (pt) | cepas bacterianas capazes de metabolizar oxalatos | |
| BR112017007375A2 (pt) | composição compreendendo oligossa¬carídeos fut2 dependentes e lacto-n-neotetraose para uso na promoção do desenvolvimento e da cognição cerebral | |
| BR112018000236A2 (pt) | composições nutricionais e métodos para a promoção do desenvolvimento cognitivo | |
| WO2016030644A3 (fr) | Procédé d'induction de la synthèse des phycobiliproteines | |
| BR112018013292A2 (pt) | ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii? | |
| BR112017006416A2 (pt) | composição nutricional para meio gastrointestinal para proporcionar perfil aperfeiçoado de microbioma e metabólico | |
| BR112013027474A2 (pt) | composições que melhoram a palatabilidade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |